cancer-associated fibroblast

Overview

Cancer-associated fibroblasts (CAFs) are activated stromal fibroblasts that reside within the tumor microenvironment and play a central role in promoting malignant progression and therapeutic resistance. These cells arise from mesenchymal lineages within tumor stroma and are phenotypically and functionally distinct from quiescent fibroblasts, characterized by markers such as fibroblast activation protein (fibroblast activation protein alpha (FAP)). CAFs exhibit spatial heterogeneity and display specialized functional states that collectively contribute to multiple aspects of tumor biology, including extracellular matrix remodeling, metabolic reprogramming, and immunosuppression. Their functional impact extends across diverse cancer types—including pancreatic adenocarcinoma, hepatocellular carcinoma, breast cancer, colorectal cancer, and oral squamous cell carcinoma—where they are emerging as key mediators of both tumor progression and resistance to immunotherapy.

The significance of CAFs in cancer biology centers on their multifaceted interactions with both malignant cells and the immune compartment. CAF-derived signaling, metabolic output (such as lactate production through the SDC1-ENO1 axis), and soluble factors shape the immunosuppressive landscape and can reprogram local immune responses through pathways involving tryptophan metabolism and STING activation. Beyond their role in promoting epithelial-mesenchymal transition and radioresistance, CAFs generate physical and biochemical barriers that limit therapeutic penetration and efficacy of both conventional and immunotherapies, including anti-PD-1 approaches. Contemporary therapeutic strategies increasingly target CAFs through multiple modalities—depletion (fibroblast activation protein alpha (FAP)-targeted approaches), normalization, and metabolic reprogramming—reflecting growing recognition that effective cancer treatment may require concurrent manipulation of the stromal compartment alongside direct targeting of tumour cells.

Recent Publications Summary

Recent studies have revealed that cancer-associated fibroblasts represent heterogeneous populations with distinct functional subtypes rather than a monolithic cell type. In hepatocellular carcinoma, hepatic stellate cells serve as a major source of CAFs, and advances in single-cell and spatial multi-omics techniques have delineated the transcriptional and phenotypic heterogeneity of these populations and their spatiotemporal dynamics within the tumor microenvironment 42599778Aug. Spatial transcriptomics integration in pancreatic ductal adenocarcinoma identified three robust CAF subtypes with differential roles, with CAF_C0 mediating amino acid and peptide transfer, CAF_C1 serving as a primary source of lipids, and CAF_C2 exhibiting distinct metabolic signatures 42144098May. Similarly, investigation of colorectal cancer revealed spatial functional specialization within specific CAF subpopulations 42143353May, while FAP-targeted therapeutic approaches have uncovered the emergence of mixed CAF populations upon treatment 42398971Jul.

CAF-mediated metabolic reprogramming has emerged as a central mechanism driving tumor progression and therapeutic resistance. In pancreatic cancer, a subset of mitophagy-competent CAFs conferred gemcitabine resistance through ZEB1-mediated activation of BNIP3-dependent mitophagy, leading to increased nucleotide secretion that competitively inhibited gemcitabine incorporation while simultaneously supplying pyrimidine metabolism substrates to tumor cells 42202065May. In breast cancer, the SDC1-ENO1 axis in CAFs promoted aerobic glycolysis and lactate accumulation, generating a lactate-rich microenvironment that not only promoted tumor stemness but also impaired cytotoxic functions of both natural killer cells and CD8+ T cells 41812066Mar. CAFs additionally contribute to lipid metabolism reprogramming within the tumor microenvironment, profoundly reshaping immune cell populations and establishing complex metabolic crosstalk that drives immune evasion 41946907Apr.

CAF-mediated immunosuppression and therapy resistance constitute major obstacles to effective cancer treatment. In hepatocellular carcinoma, WNK4 transferred via exosomes from tumor cells into CAFs promoted cysteine metabolic reprogramming in a manner that enhanced anti-PD-1 resistance while simultaneously promoting the malignant phenotypes of hepatocellular carcinoma cells 42253146Jun. In oral squamous cell carcinoma, high CAF infiltration in the invasion front was independently associated with poor five-year overall survival, alongside high infiltration of immunosuppressive M2-like tumor-associated macrophages and low cytotoxic T-lymphocyte infiltration 42219817Jun. CAFs create both physical and immunological barriers through extracellular matrix deposition and immunosuppressive factor secretion, limiting the efficacy of combination immunotherapies 42599778Aug.

Multiple therapeutic strategies have targeted CAFs to enhance treatment efficacy. Direct CAF depletion approaches, such as FAP-targeted T-cell engagers, have shown promise in preclinical models but revealed complex tumor microenvironmental adaptations upon treatment 42398971Jul. Alternative approaches have aimed to reprogram rather than deplete CAFs: normalization of CAFs combined with inhibition of matrix deposition reduced immunosuppression and enhanced immune cell infiltration 41856326Mar, while targeting the SDC1+ CAF subset with antibody-drug conjugate therapy synergized with radiotherapy, restoring radiosensitivity and remodeling the immune microenvironment 41812066Mar. PI3K inhibitors have also been shown to suppress CAF infiltration and their pro-migratory factor secretion in lung squamous cell carcinoma 41545755Jan, and CRISPR-based strategies for modifying CAFs within the tumor microenvironment demonstrate enhanced antitumor responses 41833894Mar.

What Changes, What Holds

1. Metabolic specialization defines functional CAF subtypes
REINFORCES Spatial transcriptomics reveals CAF subtypes with distinct metabolic roles—CAF_C0 mediating amino acid transfer, CAF_C1 provisioning lipids, CAF_C2 with unique metabolic profiles 42144098May—grounding the Overview's description of CAFs with "specialized functional states" in concrete mechanisms. FAP-targeted depletion unexpectedly triggers emergence of mixed CAF populations 42398971Jul, suggesting direct elimination strategies may reshape rather than durably remove the CAF compartment.

2. mitophagy and lipid metabolism enable CAF-mediated therapeutic resistance
REINFORCES BNIP3-dependent mitophagy in CAF subsets confers gemcitabine resistance through competitive nucleotide secretion 42202065May, while SDC1-ENO1-driven lactate production impairs NK and CD8+ T-cell cytotoxicity 41812066Mar. These mechanisms elaborate the Overview's account that CAF metabolic output reprograms immune responses and drives resistance. Lipid metabolism reprogramming by CAFs further extends the known pathways of stromal metabolic support for immune evasion 41946907Apr.

3. Exosomal inter-cellular signaling coordinates CAF-mediated anti-PD-1 resistance
REINFORCES tumor cell-derived WNK4 transferred via exosomes into CAFs promotes cysteine metabolic reprogramming that enhances anti-PD-1 resistance while supporting malignant phenotypes 42253146Jun. CAF infiltration independently correlates with poor survival and impaired CD8+ T-cell infiltration 42219817Jun, clinically validating the Overview's assertion that CAFs generate barriers limiting immunotherapy efficacy. Exosomal signaling provides a specific mechanism coordinating tumor-stromal resistance.

4. Subset-specific and combination CAF-targeting strategies enhance therapeutic efficacy
REINFORCES FAP-targeted T-cell engagers show efficacy but trigger complex adaptive responses 42398971Jul, suggesting durable benefit may require targeting CAF specialization rather than achieving complete elimination. CAF normalization combined with matrix inhibition enhances immune infiltration 41856326Mar, validating non-depleting strategies the Overview identifies. Multiple mechanistic approaches establish CAFs as druggable compartments, confirming the Overview's emphasis on multi-modal therapeutic strategies.

Overview update candidates: CAF metabolic specialization via distinct subtypes with defined roles; exosomal tumor-CAF signaling as a mechanism of anti-PD-1 resistance; BNIP3-dependent mitophagy conferring chemotherapy resistance; microenvironmental adaptation dynamics upon CAF-targeted depletion.